JPH0130809B2 - - Google Patents

Info

Publication number
JPH0130809B2
JPH0130809B2 JP54021281A JP2128179A JPH0130809B2 JP H0130809 B2 JPH0130809 B2 JP H0130809B2 JP 54021281 A JP54021281 A JP 54021281A JP 2128179 A JP2128179 A JP 2128179A JP H0130809 B2 JPH0130809 B2 JP H0130809B2
Authority
JP
Japan
Prior art keywords
carbamoyl
ethyl
propyl
desoxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP54021281A
Other languages
English (en)
Japanese (ja)
Other versions
JPS54141718A (en
Inventor
Baashanku Geruharuto
Emu Deiitoritsuhi Fuerikusu
Gisura Roorando
Harutoman Aruberuto
Sutanetsuku Yarosurafu
Tarukusei Rayosu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27173419&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH0130809(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of JPS54141718A publication Critical patent/JPS54141718A/ja
Publication of JPH0130809B2 publication Critical patent/JPH0130809B2/ja
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04Cyclic acetals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55583Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6062Muramyl peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2128179A 1978-02-24 1979-02-24 Novel antigen derivative and its manufacture Granted JPS54141718A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH203578 1978-02-24
CH377778 1978-04-07
CH539478 1978-05-18

Publications (2)

Publication Number Publication Date
JPS54141718A JPS54141718A (en) 1979-11-05
JPH0130809B2 true JPH0130809B2 (enrdf_load_stackoverflow) 1989-06-22

Family

ID=27173419

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2128179A Granted JPS54141718A (en) 1978-02-24 1979-02-24 Novel antigen derivative and its manufacture

Country Status (20)

Country Link
EP (1) EP0003833B2 (enrdf_load_stackoverflow)
JP (1) JPS54141718A (enrdf_load_stackoverflow)
AR (1) AR223833A1 (enrdf_load_stackoverflow)
AT (1) AT364718B (enrdf_load_stackoverflow)
AU (1) AU527549B2 (enrdf_load_stackoverflow)
CA (1) CA1138436A (enrdf_load_stackoverflow)
DD (1) DD141616A5 (enrdf_load_stackoverflow)
DK (1) DK161026C (enrdf_load_stackoverflow)
ES (2) ES477977A1 (enrdf_load_stackoverflow)
FI (1) FI66878C (enrdf_load_stackoverflow)
GB (1) GB2015534A (enrdf_load_stackoverflow)
GR (1) GR77615B (enrdf_load_stackoverflow)
HU (1) HU182011B (enrdf_load_stackoverflow)
IL (1) IL56724A (enrdf_load_stackoverflow)
NO (2) NO151201C (enrdf_load_stackoverflow)
NZ (1) NZ189756A (enrdf_load_stackoverflow)
PL (1) PL123315B1 (enrdf_load_stackoverflow)
PT (1) PT69281A (enrdf_load_stackoverflow)
SU (1) SU1055312A3 (enrdf_load_stackoverflow)
ZA (1) ZA79893B (enrdf_load_stackoverflow)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130516A (en) * 1978-03-31 1979-10-09 Yuuichi Yamamura Acyllnnacetylmuramylpeptide derivativeeantigen combination
FR2428051A1 (fr) * 1978-06-05 1980-01-04 Anvar Nouveaux composes du type muramyl-peptide et medicaments les contenant
FR2428050A1 (fr) * 1978-06-05 1980-01-04 Anvar Oligomeres de composes du type muramyl-peptide et medicaments les contenant
US4335111A (en) 1978-12-22 1982-06-15 Agence National De Valorisation De La Recherche (Anvar) Compounds associating peptidyl of aminoacyl residues to lipophilic groups and pharmaceutical compositions containing said new compounds
FR2446292A1 (fr) * 1979-01-12 1980-08-08 Anvar Muramyl-peptides fixes sur polymeres peptidiques et medicaments les contenant
FR2449697A1 (fr) 1979-02-20 1980-09-19 Anvar Nouveaux muramyl-peptides substitues sur un azote peptidique et medicaments les contenant
JPS5618996A (en) * 1979-06-21 1981-02-23 Dai Ichi Seiyaku Co Ltd Muramyldipeptide derivative
DK156252C (da) * 1979-07-31 1989-12-18 Fujisawa Pharmaceutical Co Analogifremgangsmaade til fremstilling af di-, tri- eller tetrapeptidderivater eller salte deraf
US4406889A (en) * 1980-02-15 1983-09-27 Ciba-Geigy Corporation Derivatives of aldohexoses, intermediates, processes for their manufacture, preparations containing such compounds, and their use
EP0038153A3 (en) * 1980-04-15 1982-12-22 Beecham Group Plc Modified allergens
US4368190A (en) * 1980-04-17 1983-01-11 Merck & Co., Inc. Immunologically active dipeptidyl 4-O-,6-O-acyl-2-amino-2-deoxy-D-glucose derivatives and methods for their preparation
US4497729A (en) * 1980-12-01 1985-02-05 Fujisawa Pharmaceutical Co., Ltd. Peptide, process for preparation thereof and use thereof
FR2522967B1 (fr) * 1982-03-15 1986-03-07 Anvar Conjugues d'haptenes et de muramyl-peptides, doues d'activite immunogene et compositions les contenant
US4587046A (en) * 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
FR2558165B1 (fr) * 1984-01-17 1986-07-04 Anvar Nouveaux conjugues d'oligo-muramylpeptides et compositions biologiques les contenant pour l'activation des macrophages
FR2569984B1 (fr) * 1984-09-12 1987-08-14 Anvar Molecule synthetique contenant une pluralite d'epitopes distincts, procede pour son obtention et application a la production de polyvaccins
EP3448364B1 (en) 2016-04-29 2022-02-09 Icahn School of Medicine at Mount Sinai Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
WO2018225851A1 (ja) 2017-06-09 2018-12-13 中外製薬株式会社 N-置換アミノ酸を含むペプチドの合成方法
WO2020111238A1 (ja) * 2018-11-30 2020-06-04 中外製薬株式会社 ペプチド化合物、またはアミド化合物の脱保護法および固相反応における脱樹脂方法、並びにペプチド化合物の製造方法
KR20230171435A (ko) 2021-03-19 2023-12-20 트레인드 테라퓨틱스 디스커버리, 아이엔씨. 훈련된 면역을 조절하기 위한 화합물 및 이의 사용 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH564031A5 (enrdf_load_stackoverflow) * 1968-03-29 1975-07-15 Anvar
US4186194A (en) * 1973-10-23 1980-01-29 Agence Nationale De Valorisation De La Recherche (Anvar) Water soluble agents effective as immunological adjuvants for stimulating, in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
CH613709A5 (en) * 1975-12-10 1979-10-15 Ciba Geigy Ag Process for the preparation of glucosamine derivatives
FR2343482A1 (fr) * 1976-03-10 1977-10-07 Anvar La 2- (2-acetamido-2-deoxy-3-o-d-glucopyranosyl) -d-propionyl-l-seryl-d-isoglutamine et medicaments la contenant
JPS52139018A (en) * 1976-03-10 1977-11-19 Anvar Immuno adjuvant and antiinfection adjuvant composed of mainly nnacetyll muramiccllalanyllddglutamic ester or nnacetyllmuramiccllalanylldd isoglutamic ester

Also Published As

Publication number Publication date
GB2015534A (en) 1979-09-12
EP0003833B1 (de) 1983-07-20
IL56724A0 (en) 1979-05-31
JPS54141718A (en) 1979-11-05
AU4454679A (en) 1979-08-30
ATA142079A (de) 1981-04-15
PT69281A (de) 1979-03-01
IL56724A (en) 1982-12-31
NO151088C (no) 1985-02-06
NO151088B (no) 1984-10-29
AT364718B (de) 1981-11-10
SU1055312A3 (ru) 1983-11-15
FI66878C (fi) 1984-12-10
EP0003833A3 (en) 1980-02-06
ES483558A1 (es) 1980-04-16
DD141616A5 (de) 1980-05-14
GR77615B (enrdf_load_stackoverflow) 1984-09-25
DK79779A (da) 1979-08-25
FI66878B (fi) 1984-08-31
PL213696A1 (enrdf_load_stackoverflow) 1980-07-14
EP0003833B2 (de) 1990-12-19
AU527549B2 (en) 1983-03-10
NO793993L (no) 1979-08-27
ZA79893B (en) 1980-03-26
CA1138436A (en) 1982-12-28
EP0003833A2 (de) 1979-09-05
NO151201B (no) 1984-11-19
DK161026C (da) 1991-10-28
NZ189756A (en) 1982-05-31
NO151201C (no) 1985-02-27
NO790626L (no) 1979-08-27
PL123315B1 (en) 1982-10-30
ES477977A1 (es) 1980-01-16
FI790584A7 (fi) 1979-08-25
DK161026B (da) 1991-05-21
AR223833A1 (es) 1981-09-30
HU182011B (en) 1983-12-28

Similar Documents

Publication Publication Date Title
JPH0130809B2 (enrdf_load_stackoverflow)
US4446128A (en) Antigen derivatives and processes for their preparation
ES2205231T3 (es) Procedimiento de tratamiento de la hipersensibilidad de tipo i que utilizan monofosforil lipido a.
JPH06500772A (ja) 改良されたワクチン組成物
JP2001518556A (ja) イミン形成ポリサッカライド、その調製、ならびにアジュバントおよび免疫刺激剤としてのその使用
GB1590659A (en) Immunological adjuvant constituted by the p-aminophenyl derivative of n-acetylmuramyl-l-alanyl-d-isoglutamine
US9017699B2 (en) Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulus
US4158052A (en) Oil-free adjuvant compositions containing N-acetyl-muramyl-L-alanyl-D-isoglutamine
CH640866A5 (fr) Oligomeres de composes du type muramyl-peptide et medicaments les contenant.
JPS6412279B2 (enrdf_load_stackoverflow)
WO2018231706A1 (en) Methods and compositions for substance use disorder vaccine formulations and uses thereof
WO2021038022A1 (en) New use of cyclic dinucleotides
IL165970A (en) Method of isolating biologically active fraction containing clinically acceptable native s-lipopolysaccharides obtained from bacteria producing endotoxic lipopolysaccharides
US4172125A (en) Oil-free adjuvant compositions containing N-acetyl-muramyl-L-alanyl-D-glutamic acid and method of use
US4574058A (en) Antigen derivatives and processes for their preparation
RU2095082C1 (ru) Вакцина против гельминтозов
RU2021816C1 (ru) Способ получения вакцины против холеры
RU2021817C1 (ru) Способ получения вакцины против холеры
AU731383B2 (en) Compounds for the prevention and treatment of helminth infections
KR830002059B1 (ko) 멀아밀-펲타이드형태인 신규 화합물의 제조방법
Leenaars Adjuvants in Laboratory Animals: evaluation of immunostimulating properties and side effects of Freund's complete adjuvant and alternative adjuvants in immunization procedures
JPS63500515A (ja) 高分子支持体とハプテンとムラミルペプチドとをこのムラミルペプチドの糖質部分で置換する基を介して互いに結合させることにより得られる生成物、及び該生成物を含む選択的免疫原性組成物
JPS59225118A (ja) 寄生虫寄生症を撲滅するためのエクジステロイドから誘導された活性剤